Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report
Open Access
- 28 September 2016
- journal article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 44 (1_suppl) , 109-112
Abstract
Scleromyxoedema is a rare disease with a progressive and disabling course involving dermal deposition of mucin and fibroblast proliferation; it is characterized clinically by a diffuse papular eruption, skin thickening, oedema and decreased skin flexibility, especially of the face and hands. Current therapy options are based on evidence from a limited number of case reports. The clinical manifestations and treatment of a 64-year-old man affected by scleromyxoedema with severe skin involvement of the face, arms and hands, decreased mouth opening and hypomotility of the fingers are reported. Dysphagia, asthenia and immunoglobulin G lambda monoclonal gammopathy were also present. Previous treatment with topical and systemic corticosteroids, psoralen plus ultraviolet A radiation therapy, plasmapheresis, extracorporeal photochemotherapy, hydroxychloroquine and cyclophosphamide had been unsuccessful. Treatment with intravenous immunoglobulins at a dosage of 2 g/kg monthly was started. Considerable improvements were observed after seven cycles of therapy, with recovery of skin elasticity, an increase in facial mimic movement, restoration of joint function and improvement in the modified Rodnan score. There were no observed side-effects. The patient remains in remission on monthly maintenance intravenous immunoglobulins, 2 years after initial treatment.Keywords
This publication has 16 references indexed in Scilit:
- Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patientsJournal of the American Academy of Dermatology, 2013
- Scleromyxedema and the dermato‐neuro syndrome: case report and review of the literatureJournal of Cutaneous Pathology, 2012
- Generalized papular and sclerodermoid eruption: ScleromyxedemaIndian Journal of Dermatology, Venereology and Leprology, 2010
- Arndt–Gottron scleromyxoedema: successful therapy with intravenous immunoglobulinsBritish Journal of Dermatology, 2007
- Lichen Myxedematosus (Papular Mucinosis): New Concepts and Perspectives for an Old DiseaseSeminars in Cutaneous Medicine and Surgery, 2006
- Adverse events associated with intravenous immunoglobulin therapyInternational Immunopharmacology, 2006
- Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulinsJournal of the European Academy of Dermatology and Venereology, 2005
- Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedemaJournal of the American Academy of Dermatology, 2001
- Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.1993
- Lichen Myxedematosus (Differentiation from Cutaneous Myxedemas or Mucoid States)Journal of Investigative Dermatology, 1953